Related by context. All words. (Click for frequent words.) 73 gefitinib Iressa 72 mTOR inhibitors 72 MGd 71 galiximab 71 PROCHYMAL 71 relapsed MM 71 MAGE A3 ASCI 71 trastuzumab Herceptin ® 71 hematopoietic cancers 71 taxane resistant 71 liver metastasis 71 Vectibix monotherapy 71 recurrent GBM 71 antiresorptive 71 recurrent glioblastoma multiforme 71 lenalidomide dexamethasone 70 antitumor effect 70 ovarian carcinoma 70 riociguat 70 rtPA 70 preoperative chemotherapy 70 cediranib 70 antiproliferative effects 70 colorectal liver metastases 70 anti angiogenic agents 70 prostate carcinoma 70 HER2 overexpression 70 perioperatively 70 murine models 70 ZOLINZA 70 chemosensitivity 70 biliary tract cancer 70 immune modulating 70 androgen ablation 70 demonstrated antitumor activity 70 thalidomide Thalomid 70 enzastaurin 69 tumor histology 69 unresectable tumors 69 antioxidant supplementation 69 cilengitide 69 cisplatin chemotherapy 69 pegylated liposomal doxorubicin 69 pancreatic adenocarcinoma 69 erlotinib Tarceva 69 postoperative chemotherapy 69 antiangiogenesis 69 haematologic 69 imatinib Gleevec 69 EGFR tyrosine kinase inhibitors 69 CYT# potent vascular disrupting 69 rituximab Rituxan 69 null responder 69 concurrent chemoradiation 69 Prognostic factors 69 goserelin 69 viral kinetics 69 antiangiogenic agents 69 taxane therapy 69 antiangiogenic 69 mRCC 69 HER2 expression 69 tipranavir ritonavir 69 flavopiridol 69 IFN beta 69 pain palliation 69 APTIVUS r 69 KRAS status 69 IV bisphosphonates 69 trabectedin 69 Doxil ® 69 chemoradiotherapy 69 bortezomib Velcade 69 relapsed ovarian cancer 69 busulfan 69 intravenous cyclophosphamide 68 CTAP# Capsules 68 renoprotective 68 intratumoral 68 prostate cancer CaP 68 mycophenolate mofetil 68 selective modulator 68 immunosuppressive regimen 68 allogeneic HSCT 68 antimetabolites 68 Akt activation 68 KRAS mutations occur 68 neratinib 68 therapeutic regimens 68 Aplidin 68 GnRH agonists 68 β blockers 68 DAPT 68 paricalcitol 68 locoregional recurrence 68 isoproterenol 68 cisplatin resistant 68 bezafibrate 68 baseline LDH 68 anthracycline chemotherapy 68 lesional 68 adjuvant radiotherapy 68 pharmacodynamic effects 68 cytotoxic therapies 68 Xanafide 68 cinacalcet 68 prospectively stratified 68 metastatic malignant 68 Aggrastat ® tirofiban hydrochloride 68 K ras mutations 68 triglyceride lowering 68 alkylating agent 68 proliferative disorders 68 interleukin IL -# 68 receptor inhibitor 68 Degarelix 68 rFVIIa 68 pharmacologic intervention 68 prostate cancer PCa 68 prognostic indicators 68 PSMA ADC 68 T#I [002] 68 membranous nephropathy 68 interferon ribavirin 68 fulvestrant 68 pamidronate 68 clevidipine 68 mutated K ras 67 operable breast cancer 67 mTOR inhibition 67 endocrine therapies 67 paclitaxel Taxol R 67 circulating EPCs 67 refractory prostate cancer 67 carcinoid 67 differentiated thyroid 67 TNF antagonist 67 cisplatin gemcitabine 67 tumor hypoxia 67 metastatic colorectal 67 locoregional disease 67 pharmacodynamic PD 67 HBeAg negative 67 fosbretabulin 67 LHRH receptor positive 67 EGFR inhibitors 67 antirheumatic 67 erlotinib Tarceva ® 67 Gleevec resistant 67 colorectal adenocarcinoma 67 Virulizin ® 67 adriamycin 67 vidofludimus 67 KRAS mutation 67 lactate dehydrogenase LDH 67 CBLC# 67 inecalcitol 67 lumiliximab 67 anticholinergic agents 67 hormone refractory 67 lipid lowering therapies 67 mecamylamine 67 antimetabolite 67 papillary renal cell carcinoma 67 Pemetrexed 67 EndoTAGTM 1 67 Enzastaurin 67 chemoresistant 67 gastrointestinal stromal tumors GIST 67 pharmacokinetic interactions 67 cytoprotective 67 etanercept Enbrel 67 cardiac repolarization 67 ELACYT 67 tamoxifen Nolvadex ® 67 NATRECOR ® 67 recurrent glioblastoma 67 Gliadel Wafer 67 potent antiproliferative 67 radiotherapy RT 67 sipuleucel T 67 cytopenias 67 metastatic malignant melanoma 67 skeletal metastases 67 Telintra 67 octreotide LAR 67 glomerular filtration 67 immunomodulation 67 OHR/AVR# 67 forodesine 67 estramustine 67 superficial bladder cancer 67 BENICAR HCT 67 antiplatelet therapies 67 PNH patients 67 tumorigenicity 67 Fulvestrant 67 Sudhir Agrawal D.Phil 67 ritonavir boosted 67 somatostatin analogues 67 xenograft models 67 stratifying patients 67 Temsirolimus 67 squamous cell lung cancer 67 angiographic outcomes 67 HuLuc# 67 rituximab monotherapy 67 ALK inhibitors 67 HER2 positive cancers 67 corticosteroid dexamethasone 67 urothelial cancer 67 FDG PET imaging 67 uric acid lowering 67 Platinol ® cisplatin 67 spontaneous regression 67 pyridostigmine 67 microwave hyperthermia 67 alvespimycin 67 irinotecan chemotherapy 67 transarterial 67 medically inoperable 67 alefacept 67 immunosuppressive therapies 67 Insulin detemir 67 EGFR TKI 67 lymphocytosis 67 Interferon beta 67 aromatase inhibitors AIs 67 cervical lymph nodes 67 nodal metastasis 67 amifostine 67 pertuzumab 67 thrombotic complications 66 neoadjuvant 66 EGFR receptor 66 VAPRISOL 66 EGFR mutation positive 66 retaspimycin 66 standard chemotherapy regimens 66 Akt inhibitor 66 nab paclitaxel 66 pretransplant 66 nicardipine 66 paclitaxel eluting stents 66 CR nPR 66 nutlin 3a 66 radiochemotherapy 66 ZACTIMA 66 mouse xenograft models 66 adalimumab Humira 66 receptor tyrosine kinase inhibitor 66 radiosensitivity 66 decitabine 66 lapatinib Tykerb 66 neoadjuvant therapy 66 antiangiogenic agent 66 endothelial activation 66 paclitaxel poliglumex 66 neuroregenerative 66 Bisphosphonate 66 docetaxel Taxotere ® 66 intravenous bisphosphonates 66 androgen suppression 66 angiographically 66 Adjuvant chemotherapy 66 gemcitabine carboplatin 66 fallopian tube cancers 66 corticosteroid therapy 66 EGFR tyrosine kinase inhibitor 66 ACTEMRA TM 66 symptomatic paroxysmal AF 66 refractory colorectal cancer 66 surrogate endpoint 66 antiplatelet medications 66 lung metastasis 66 antiestrogen 66 CIMZIA ™ 66 metastatic uveal melanoma 66 FUSILEV enhances 66 antibody mediated 66 LHRH 66 histological subtype 66 Subgroup analysis 66 follicular lymphomas 66 erythropoietic 66 BRCA deficient 66 Flu Cy 66 VEGF inhibitors 66 Kinoid 66 Teriflunomide 66 YONDELIS 66 oral anticoagulation 66 Aflibercept 66 Vidaza azacitidine 66 neurotrophic 66 EGFR inhibition 66 docetaxel prednisone 66 tumor subtypes 66 GnRH agonist 66 Alequel 66 pediatric acute lymphoblastic 66 heavily pretreated 66 neoadjuvant chemotherapy 66 TNF α 66 platelet inhibitor 66 liposomal doxorubicin 66 refractory metastatic 66 epithelial tumors 66 Xelox 66 panobinostat 66 Zevalin consolidation 66 immune modulatory 66 serous ovarian cancer 66 trans retinoic acid 66 eculizumab therapy 66 patients receiving myelosuppressive 66 Anthracycline 66 mapatumumab 66 metastatic lymph nodes 66 EndoTAG TM -1 66 platelet reactivity 66 metastatic neuroendocrine tumors 66 Apoptone 66 visilizumab 66 immuno modulatory 66 thyroid carcinoma 66 BRAF inhibitors 66 prognostic variables 66 pharmacodynamic parameters 66 ISTODAX 66 sorafenib Nexavar 66 Hedgehog inhibitor 66 intermittent dosing 66 motesanib 66 gastric adenocarcinoma 66 dasatinib Sprycel 66 castrate resistant 66 hormone receptor negative 66 splenectomized patients 66 Trastuzumab 66 Ceplene/IL-2 66 gemcitabine Gemzar ® 66 Vidaza ® 66 radioimmunotherapy RIT 66 lymphomas leukemias 66 LHRH agonists 66 invasive candidiasis 66 peritoneal carcinomatosis 66 urothelial carcinoma 66 SSc 66 bevacizumab Avastin ® 66 cytoreduction 66 myeloablative 66 immunomodulatory agents 66 locoregional 66 MYLOTARG 66 AST ALT 66 dexrazoxane 66 VEGF inhibition 66 kidney urologic 66 cytotoxic effects 66 gemcitabine Gemzar 66 nonmetastatic 66 hyperalgesia 66 aspirin clopidogrel 66 cardiotoxic 66 Afatinib 66 metaglidasen 66 pretargeting 66 alkaline phosphatase ALP 65 chemoembolization 65 canakinumab 65 decompensated cirrhosis 65 malignant ascites 65 angiogenesis inhibition 65 paclitaxel Taxol ® 65 liposomal amphotericin B 65 cytoreductive nephrectomy 65 castrate resistant prostate cancer 65 Hepatocellular Carcinoma HCC 65 castration resistant prostate cancer 65 lenalidomide Revlimid R 65 ToGA 65 dosage regimens 65 p# biomarker 65 postoperative radiotherapy 65 neuroinflammatory 65 infliximab Remicade 65 elotuzumab 65 chemopreventive agent 65 visceral metastases 65 steroid dexamethasone 65 zoledronate 65 LHRH agonist 65 Allovectin 7 ® 65 eosinophil count 65 azacytidine 65 plasminogen activators 65 adjuvant systemic 65 LV dysfunction 65 Tumor Response 65 docetaxel chemotherapy 65 tumor necrosis 65 antiandrogens 65 heavily pretreated patients 65 metastatic RCC 65 mucinous 65 surgical debulking 65 transrectal ultrasound guided 65 liposome formulation 65 JAK inhibitors 65 fluvastatin 65 adjuvant cisplatin 65 antiandrogen 65 paclitaxel cisplatin 65 CIMZIA TM 65 Hypotension 65 certolizumab 65 elevated LDH 65 CINTREDEKIN BESUDOTOX 65 adverse cytogenetics 65 humanised monoclonal antibody 65 oral prodrug 65 malignant pleural mesothelioma 65 lamivudine refractory patients 65 velafermin 65 imatinib therapy 65 NMIBC 65 serum biomarkers 65 tanespimycin 65 dose escalation phase 65 Cloretazine 65 prognostic indicator 65 mediated inhibition 65 efaproxiral 65 HER2 positive metastatic breast 65 ADVEXIN therapy 65 IFN α 65 bleomycin 65 Proxinium TM 65 vasoactive 65 coinfected patients 65 HIV HCV coinfected 65 sorafenib tablets 65 Adjuvant therapy 65 humoral responses 65 flutamide 65 metaplasia 65 VA# [002] 65 telomerase inhibition 65 nonmetastatic prostate cancer 65 STRIDE PD 65 PARP inhibition 65 chemoradiation therapy 65 p# activation 65 gemcitabine cisplatin 65 ischemia reperfusion 65 Pharmacokinetic studies 65 florbetaben 65 Squalamine 65 neoadjuvant treatment 65 TNF alpha inhibitor 65 BrachySil TM 65 Cyclin E 65 anticancer therapy 65 chemoprotective 65 chemotherapy docetaxel 65 Velcade bortezomib 65 ispinesib administered 65 serum urate levels 65 genotypic resistance 65 FDG-PET/CT 65 potent suppressor 65 antiretroviral naïve 65 Campath alemtuzumab 65 samalizumab 65 androgen independent 65 ALB # 65 p# MAPK 65 oral deforolimus 65 argatroban 65 EGFr 65 refractory CLL 65 ruboxistaurin 65 serum urate 65 choroidal vasculopathy 65 microtubule targeting 65 colon carcinoma 65 hypotensive 65 EGFRIs 65 teriflunomide 65 GW# [003] 65 radioiodine therapy 65 hMG 65 adjuvant therapies 65 intact parathyroid hormone 65 hepatorenal syndrome 65 DAVANAT 65 Navelbine 65 elacytarabine 65 TNF alpha antagonist 65 mutated KRAS 65 esophagogastric 65 redox active 65 renal cell carcinomas 65 myopathy rhabdomyolysis 65 sorafenib Nexavar ® 65 radiolabeled TM# 65 paclitaxel Taxol 65 treating neuropathic pain 65 NAbs 65 adjuvant tamoxifen 65 refractory AML 65 relapsed SCLC 65 diagnostic biomarker 65 FOSRENOL ® 65 pouchitis 65 regorafenib 65 CYP#D# inhibitor 65 Surgical resection 65 cytotoxic therapy 65 achieved CCyR 65 pramlintide metreleptin combination 65 taxane chemotherapy 65 Panzem R NCD 65 immunosuppressive regimens 65 abacavir lamivudine 65 anti angiogenic therapy 65 seminomas 65 HGS ETR2 65 relapsed multiple myeloma 65 ziconotide 65 Dasatinib 65 Lisofylline 65 Dacogen decitabine 65 gallium nitrate 65 extramedullary 65 Lymph node 65 Aptivus ® 65 insulin sensitizing 65 glycosylated hemoglobin HbA1c 65 denileukin diftitox 65 subcutaneous immunoglobulin 65 systemic hypotension 65 NCCN guidelines 65 Arranon 65 CYP #A# 65 perioperative morbidity 65 Chronic pancreatitis 65 rituximab refractory 65 pCR 65 chemotherapeutic drug 65 QTc prolongation 65 renal denervation 65 oral rivaroxaban 65 hormone deprivation 65 neurologic progression 65 vWF 65 BMS# 65 pomalidomide 65 previously untreated follicular 65 CHOP chemotherapy 65 TKI therapy 65 IOP lowering 65 ixabepilone 65 PEGPH# 65 sarcomatoid 65 PXD# 65 ara C 65 hemodynamic variables 65 thetreatment 65 DOXIL 65 pharmacodynamic markers 65 ablative therapy 65 imexon 65 methotrexate monotherapy 65 secondary hyperparathyroidism 65 androgen deprivation 65 Bezielle 65 coadministration 65 aminotransferases 65 drug eluting stent implantation 65 ciclosporin 65 hepatic fibrosis 65 ER CHOP 65 metastatic GIST 65 CD# antibody [001] 65 Onconase 65 CINQUIL 65 Myelodysplastic Syndrome MDS 65 colorectal adenoma 65 prognostic markers 65 achieved sustained virological 65 trastuzumab DM1 65 edifoligide 65 thromboembolic disease 65 liposomal formulation 64 mutated KRAS gene 64 IMC A# 64 glycated hemoglobin levels 64 factor Xa inhibitor 64 CIPN 64 temozolomide TMZ 64 dnaJP1 64 recurrent venous thromboembolism 64 postoperative AF 64 EDARBI 64 haematopoietic 64 thoracoscopic lobectomy 64 CIMZIA TM certolizumab pegol 64 thrombocytopenic 64 chlorambucil 64 antisense inhibitors 64 Gefitinib 64 antiarrhythmic 64 metastatic renal cell carcinoma 64 Helicobacter pylori eradication 64 cobiprostone 64 EXJADE 64 percutaneous biopsy 64 antiplatelet drugs 64 bovine thrombin 64 KRAS oncogene 64 MMP inhibitors 64 uridine triacetate 64 oral clodronate 64 Zybrestat 64 FOLFOX6 64 TOP2A 64 interferon beta therapy 64 mitochondrial toxicity 64 immune modulator 64 Naive Patients 64 Genz # 64 unconjugated 64 potentially hepatotoxic 64 Pertuzumab 64 thyrotropin 64 TLK# 64 kinase inhibition 64 interferon alfa 64 TG# [003] 64 mitoxantrone plus 64 EGFR HER2 64 metastatic gastric 64 pan HDAC inhibitor 64 thiopurine 64 NATRECOR R 64 nalbuphine ER 64 cMET 64 neuroleptic 64 pegylated interferon ribavirin 64 prostate cancer CRPC 64 Erlotinib 64 effector function 64 LHRH analogues 64 pentoxifylline 64 RRM1 64 adrenalectomy 64 rHuEPO 64 pDCs 64 MP4OX 64 durable remissions 64 BRAF V#E mutation 64 abacavir Ziagen 64 beta interferons 64 sargramostim 64 systemically administered 64 FOLFIRINOX 64 antihypertensive therapy 64 standard chemotherapy regimen 64 external beam radiotherapy 64 FASLODEX 64 GIST tumors 64 recurrent metastatic 64 BCG refractory 64 gastric carcinoma 64 preclinically 64 neointimal hyperplasia 64 T2DM 64 androgen hormone 64 BEXXAR Therapeutic Regimen 64 APOPTONE 64 CLORETAZINE TM VNP#M 64 adult chronic ITP 64 uricase 64 cranial irradiation 64 intracranial hemorrhage ICH 64 interferon γ 64 hepatic metastases 64 ß blockers 64 glial tumors 64 indibulin 64 NPM1 mutation 64 Cremophor 64 sunitinib Sutent 64 5alpha reductase 64 tarenflurbil 64 pharmacologically active isomer 64 Surgical excision 64 serum phosphate 64 HuMax EGFr 64 synovial cells 64 ATACAND 64 thrombolytic agents 64 EGFR TKIs 64 imetelstat 64 RhuDex TM 64 Traficet EN 64 bacillus Calmette Guerin 64 ICD therapy 64 Cytoxan 64 octreotide 64 labetalol 64 CA4P 64 Sipuleucel T 64 PI3K Akt 64 radiolabeled 64 SPRYCEL ® 64 Capesaris 64 GHRH 64 LCP Tacro TM 64 BENICAR 64 doxorubicin HCl 64 Cimzia TM 64 T1a 64 neointimal 64 hematological parameters 64 antiarrhythmic drugs 64 calcineurin inhibitors 64 varespladib 64 TTF Therapy 64 fusion enhancers 64 #I TM# 64 pancreatic prostate 64 beta1 integrin 64 Deforolimus 64 localized renal 64 pro angiogenic 64 allergic airway inflammation 64 myeloproliferative diseases 64 endometrial hyperplasia 64 oblimersen 64 antiarrhythmic drug 64 Neoadjuvant 64 postprandial glycemia 64 relapsed AML 64 tumor lysis syndrome 64 resectable 64 oral antidiabetic medication 64 anti angiogenic drugs 64 H. pylori eradication 64 pancreatic carcinoma 64 overt nephropathy 64 Natalizumab 64 omega interferon 64 RAS blockers 64 hypervascular tumors 64 KRAS mutations 64 ON #.Na 64 HCV protease inhibitors 64 conventional DMARDs 64 efficacy evaluable 64 CaPre TM 64 carboplatin paclitaxel 64 fibrotic disease 64 serum calcium levels 64 immunomodulatory properties 64 oxysterols 64 ABVD 64 Abiraterone acetate 64 glargine 64 Lenalidomide 64 chronic thromboembolic pulmonary 64 histologically proven 64 ALA PDT 64 lymphoma subtypes 64 alpha fetoprotein AFP 64 etoposide 64 osteoblastic 64 direct thrombin inhibitors 64 BoNTA 64 HER2 positivity 64 Amplimexon 64 Febrile neutropenia 64 tryptase 64 B7 H3 64 aromatase inhibitor therapy 64 PROSTVAC VF 64 relapsing remitting MS RRMS 64 DFMO 64 palifermin 64 multivessel disease 64 Tyrima 64 thienopyridines 64 palliative radiotherapy 64 lung epithelium 64 HepG2 cells 64 cardioprotective effects 64 Radical prostatectomy 64 hepatic toxicity 64 RRMS patients 64 clinicopathological features 64 F FDG PET 64 hepatic arterial 64 completely resected 64 platelet dysfunction 64 antitumour activity 64 cTnI 64 prostate carcinomas 64 hyperoxaluria 64 AA Amyloidosis 64 plasma uric acid 64 IGF IR 64 somatostatin analog 64 atrial tachyarrhythmias 64 unresectable stage 64 AGHD 64 AChE inhibitors 64 calcium antagonists 64 phase IIb trial 64 epoetin alpha 64 cytotoxic chemotherapy 64 idarubicin 64 olmesartan 64 osteoblast 64 glatiramer 64 oncologic outcomes 64 progesterone receptor negative 64 recombinant erythropoietin 64 diabetic kidney 64 Known hypersensitivity 64 isoenzyme 64 platelet inhibition 64 ErbB2 positive 64 nondiabetic patients 64 neovascularization 64 TRV# [001] 64 trastuzumab Herceptin R 64 mGlu2 3 64 TACI Ig 64 Thal Dex 64 Fluorouracil 64 hA# 64 gonadotrophin releasing hormone 64 compound AEZS 64 pancreatic ductal 64 antiemetics 64 evaluating tivozanib 64 HIF 1a 64 novel VDA molecule 64 carcinoid tumors 64 clodronate 64 CMV infections 64 intima media thickness 64 P selectin 64 Rituxan rituximab 64 posttransplant 64 IGF 1R inhibitor 64 Neuvenge 64 TRAIL induced apoptosis 64 anti leukemic 64 intravesical 64 VADT 64 antitumor effects 64 renal carcinoma 64 antithrombotic therapy 64 sentinel lymph node biopsy 64 5 Fluorouracil 64 gadobutrol 64 refractory NSCLC 64 ovarian suppression 64 Hepatotoxicity 64 tumor subtype 64 plasma pharmacokinetics 64 TURBT 64 ACZ# 64 bronchodilatory 64 intensive lipid lowering 64 alpha interferons 64 antihormonal 64 leukocyte count 64 EBRT 64 ERK1 2 64 DCVax R 64 hepatoma 64 LRP5 64 ORENCIA ® 64 GRN# 64 PSN# [001] 64 TNFa 64 biochemical relapse 64 clinically meaningful reductions 64 beta 1a 64 sunitinib malate 64 vaso occlusive crisis 64 IFN β 64 bendamustine 64 primary hyperparathyroidism 64 virologic responses 64 bardoxolone methyl 64 agomelatine 64 lenalidomide Revlimid 64 letrozole Femara 64 bicalutamide 64 Proellex TM 64 #F FDG 64 anagrelide 64 ENMD # 64 posttreatment 64 multicenter Phase II 64 TroVax ® 64 somatostatin analogs 64 mineralocorticoid 64 antitumor efficacy 64 genomic alterations 64 AKT inhibitor 64 maximally tolerated lipid lowering 64 ImmunoVEX HSV2 64 hydroxychloroquine 64 Ceflatonin 64 relapsed ALL 64 adjuvant trastuzumab 64 selenium supplementation 64 Subgroup analyzes 64 Marqibo TM 64 Inhaled nitric oxide 64 systemic antifungal 63 inflammatory cytokine 63 Src inhibitors 63 cardioprotection 63 nucleoside analog 63 resynchronization therapy 63 PKC# 63 Avastin Tarceva 63 metastatic hormone refractory 63 poststroke depression 63 potent inducer 63 nonrandomized 63 Cardiotoxicity 63 Roche Xeloda 63 corifollitropin alfa 63 EpCAM 63 PSADT 63 cervical lymph node 63 ACCORD Lipid 63 zotarolimus 63 elevated LDL cholesterol 63 microtubule inhibitor 63 Darinaparsin 63 HBeAg seroconversion 63 taxotere 63 PITX2 methylation 63 Imprime PGG 63 thromboxane A2 63 intratumoral injection 63 tipranavir r 63 adrenoceptor 63 antihyperglycemic 63 intraperitoneal chemotherapy 63 TLE3 63 adenomatous 63 ibandronate 63 schizophrenia CIAS 63 Paliperidone 63 clomipramine 63 neovascular 63 pegfilgrastim 63 FDG uptake 63 AEG# 63 Pyridorin 63 natriuretic peptides 63 idraparinux 63 node metastases 63 prospectively defined 63 BRIM2 63 Toxicities 63 multitargeted 63 FOLFIRI alone 63 aT cell 63 protein tyrosine phosphatase 1B 63 maximally tolerated 63 thalidomide dexamethasone 63 IFN γ 63 Immunohistochemical analysis 63 Taxol ® 63 steatohepatitis 63 Thalomid ® 63 Radiofrequency ablation 63 elevated transaminases 63 intracoronary 63 curative resection 63 HDAC inhibition 63 S. maltophilia 63 selective agonists 63 Insulin PH# 63 EGFR mutation status 63 iniparib BSI 63 hypoxic tumors